CL2018001345A1 - Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. - Google Patents
Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.Info
- Publication number
- CL2018001345A1 CL2018001345A1 CL2018001345A CL2018001345A CL2018001345A1 CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1 CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- disease
- trihydroxytetrahydro
- cyanoacetyl
- methylpiperidin
- Prior art date
Links
- -1 (methyl) (amino) Chemical class 0.000 title abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
- 208000011231 Crohn disease Diseases 0.000 title abstract 2
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 title abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259273P | 2015-11-24 | 2015-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001345A1 true CL2018001345A1 (es) | 2018-06-22 |
Family
ID=57518004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001345A CL2018001345A1 (es) | 2015-11-24 | 2018-05-18 | Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. |
Country Status (33)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2840650T3 (es) | 2015-11-03 | 2021-07-07 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| EP3371184A1 (en) | 2015-11-03 | 2018-09-12 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| AU2016359494B2 (en) | 2015-11-24 | 2021-01-07 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| US10472366B2 (en) | 2017-03-08 | 2019-11-12 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| US10233174B2 (en) * | 2017-05-23 | 2019-03-19 | Theravance Biopharma R&D Ip, Llc | Thiocarbamate prodrugs of tofacitinib |
| WO2018226732A1 (en) * | 2017-06-05 | 2018-12-13 | Flagship Pioneering Innovations V, Inc. | Multibiotic agents and methods of using the same |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| WO2019182322A1 (ko) * | 2018-03-20 | 2019-09-26 | 삼진제약주식회사 | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| CN111094314B (zh) * | 2018-08-15 | 2022-08-12 | 江苏豪森药业集团有限公司 | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 |
| EP3847158A1 (en) * | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| CN109134564B (zh) * | 2018-09-21 | 2022-03-11 | 合肥锐思生物医药有限公司 | 乳果糖糖苷衍生物、其制备方法及其用途 |
| EP3880836A4 (en) * | 2018-11-15 | 2022-11-16 | Janssen Biotech, Inc. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO INFLAMMATORY BOWEL DISEASE THERAPY |
| PH12021551455A1 (en) * | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3146560A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| MY209459A (en) | 2019-07-10 | 2025-07-09 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US20210139857A1 (en) * | 2019-11-13 | 2021-05-13 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230107927A1 (en) * | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| WO2021231272A1 (en) * | 2020-05-14 | 2021-11-18 | Theravance Biopharma R&D Ip, Llc | Administration of gut-selective jak3 inhibitor |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| WO2022087313A1 (en) * | 2020-10-22 | 2022-04-28 | Progenity, Inc. | Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| IL309840A (en) * | 2021-07-20 | 2024-02-01 | Coval Biopharma Shanghai Co Ltd | An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof |
| WO2023225463A2 (en) * | 2022-05-14 | 2023-11-23 | 3-D Matrix, Ltd. | Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract |
| CN115073543B (zh) * | 2022-07-20 | 2022-11-15 | 北京普祺医药科技股份有限公司 | 一种jak抑制剂的化合物前药及其制备与应用 |
| CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| WO2024039599A1 (en) | 2022-08-17 | 2024-02-22 | Transcend Therapeutics, Inc. | Phenethylamines and cathinones precursors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022334A1 (en) | 1992-05-04 | 1993-11-11 | Sri International | Pharmaceutical compositions and methods for colonic delivery of corticosteroids |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| PT1382339E (pt) | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| CN105541847B (zh) | 2009-10-09 | 2019-08-16 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
| WO2011079249A2 (en) | 2009-12-23 | 2011-06-30 | Glycomyr, Inc. | Use of vitamin d glycosides and sulfates for treatment of disease |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| WO2011097087A1 (en) * | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
| US20130109720A1 (en) | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
| AU2014273983A1 (en) | 2013-05-31 | 2015-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for the therapeutic delivery |
| ES2742179T3 (es) * | 2014-06-24 | 2020-02-13 | Inst Nat Sante Rech Med | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino |
| AU2016359494B2 (en) | 2015-11-24 | 2021-01-07 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease |
| WO2017106957A1 (en) | 2015-12-23 | 2017-06-29 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106496233B (zh) | 2016-09-26 | 2018-05-15 | 东南大学 | 吡咯并嘧啶类化合物、其制备方法及其用途 |
-
2016
- 2016-11-22 AU AU2016359494A patent/AU2016359494B2/en not_active Ceased
- 2016-11-22 HR HRP20200561TT patent/HRP20200561T1/hr unknown
- 2016-11-22 WO PCT/US2016/063254 patent/WO2017091544A1/en not_active Ceased
- 2016-11-22 ME MEP-2020-126A patent/ME03757B/me unknown
- 2016-11-22 CA CA3003283A patent/CA3003283A1/en not_active Abandoned
- 2016-11-22 PL PL16808876T patent/PL3380486T3/pl unknown
- 2016-11-22 RS RS20200508A patent/RS60237B1/sr unknown
- 2016-11-22 KR KR1020187017879A patent/KR20180080330A/ko not_active Withdrawn
- 2016-11-22 ES ES16808876T patent/ES2784523T3/es active Active
- 2016-11-22 JP JP2018526682A patent/JP6778747B2/ja active Active
- 2016-11-22 MX MX2018006282A patent/MX383107B/es unknown
- 2016-11-22 SM SM20200242T patent/SMT202000242T1/it unknown
- 2016-11-22 US US15/358,462 patent/US10435428B2/en active Active
- 2016-11-22 HU HUE16808876A patent/HUE049775T2/hu unknown
- 2016-11-22 NZ NZ742574A patent/NZ742574A/en not_active IP Right Cessation
- 2016-11-22 BR BR112018010650A patent/BR112018010650A8/pt not_active IP Right Cessation
- 2016-11-22 SG SG11201803686UA patent/SG11201803686UA/en unknown
- 2016-11-22 EP EP16808876.3A patent/EP3380486B1/en active Active
- 2016-11-22 MY MYPI2018701637A patent/MY189979A/en unknown
- 2016-11-22 CN CN201680068165.XA patent/CN108290918B/zh active Active
- 2016-11-22 UA UAA201806963A patent/UA121270C2/uk unknown
- 2016-11-22 LT LTEP16808876.3T patent/LT3380486T/lt unknown
- 2016-11-22 TW TW105138180A patent/TWI703147B/zh not_active IP Right Cessation
- 2016-11-22 SI SI201630741T patent/SI3380486T1/sl unknown
- 2016-11-22 EA EA201891248A patent/EA035816B1/ru unknown
- 2016-11-22 PT PT168088763T patent/PT3380486T/pt unknown
- 2016-11-22 DK DK16808876.3T patent/DK3380486T3/da active
-
2018
- 2018-05-01 IL IL259076A patent/IL259076B/en active IP Right Grant
- 2018-05-07 ZA ZA2018/02967A patent/ZA201802967B/en unknown
- 2018-05-15 PH PH12018501037A patent/PH12018501037A1/en unknown
- 2018-05-18 CL CL2018001345A patent/CL2018001345A1/es unknown
- 2018-05-22 CO CONC2018/0005327A patent/CO2018005327A2/es unknown
-
2019
- 2019-08-29 US US16/555,222 patent/US10961267B2/en active Active
-
2020
- 2020-05-13 CY CY20201100447T patent/CY1122918T1/el unknown
- 2020-08-25 JP JP2020141651A patent/JP2020196742A/ja active Pending
-
2021
- 2021-02-22 US US17/249,126 patent/US11608354B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001345A1 (es) | Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. | |
| HK1255102A1 (zh) | 杂环化合物及其应用 | |
| EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| IN2014KN00948A (enExample) | ||
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| EA201600622A1 (ru) | Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4 | |
| EP3393647A4 (en) | PROCESS FOR CAPACITING SOLUBLE BIOLOGICS, THERAPEUTICS AND CONTRASTANTS | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| MY193728A (en) | Muscarinic receptor agonists | |
| PH12018500653A1 (en) | Salts and solid forms of monobactam antibiotic | |
| HK1206021A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| IT1399223B1 (it) | Apparato per lavorare cornici di infissi. | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| WO2013109972A3 (en) | Therapeutic compounds | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| IL261196A (en) | A pharmaceutical preparation for cancer, containing a polyphenol compound as an active ingredient | |
| EP3103453A4 (en) | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| EP3978033A4 (en) | RK POLYPEPTIDE RADIOPHARMACEUTICAL FOR TARGETING HER2 AND METHODS OF PRODUCTION | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| EP3212640A4 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| WO2015191681A3 (en) | Substituted pyridinones as mgat2 inhibitors |